Turner White CommunicationsAbout TWCSubscribeContact TWCHomeSearch
Hospital PhysicianJCOMSMPBRMsCart
Current Contents
Where We Are Indexed
Past Issue Archives
Clinical Communication
In Review
Editorial Board
Information for Authors
Author Form

Reprints, Permissions, & Copyright
Site Map
BACK ISSUE articles are $15 each.
International credit cards NOT accepted.

JCOM Paid Subscribers
user name:
Forgot password?

JCOM Abstract

J Clin Outcomes Manage 
2010 Oct;17(10):470-479
Update on prostate cancer screening
McCormick KA, Osman NY, Pomerantz MM

Abstract Objective: To provide an overview of the evidence examining the risks and benefits of prostate cancer screening with prostate-specific antigen (PSA). Methods: Review of the literature. Results: Prostate cancer poses a significant health burden in the United States. Screening for prostate cancer with PSA, although controversial, is common in the primary care setting. PSA-based screening is criticized for its low specificity, with many false-positive results. Screening also commonly results in the diagnosis of clinically insignificant prostate cancer, exposing many men to unnecessary treatments with potentially significant side effects. There is substantial indirect evidence to support a mortality benefit for screening, possibly justifying the use of PSA despite its shortcomings. However, randomized controlled trials to date have not definitively established that PSA-based screening reduces the rate of death from prostate cancer. Other areas of controversy include the age at which to start screening, particularly among those at increased risk based on race or family history. The optimal PSA threshold at which to refer for biopsy is also widely debated. Considerable efforts have been made to incorporate other laboratory variables to improve the performance of the PSA test. Conclusions: Prostate cancer screening is a common practice in the United States. While there is likely at least a modest mortality benefit to screening, this comes at the cost of diagnosing and treating clinically insignificant prostate cancer. Prior to screening, primary care providers should have a discussion with patients about the potential risks and benefits, helping patients to make an informed, values-based decision.

Case-Based Review

Search the Turner White index to find abstracts of articles published in JCOM.

New issues are posted one month following publication of the printed journal.

View past issue archives:    2013    2012    2011    2010    2009    2008    2007
   2006    2005    2004    2003     2002     2001     2000     1999

Hospital Physician     JCOM     Seminars in Medical Practice
Hospital Physician Board Review Manuals
About TWC    Subscribe    Contact TWC    Home    Search   Site Map

Copyright © 2018, Turner White Communications
Updated 1/20/14 • jdw